Related references
Note: Only part of the references are listed.Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma
Antonio Silvani et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
Guangrong Lu et al.
FRONTIERS IN NEUROLOGY (2019)
LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
Timothy Cloughesy et al.
NEURO-ONCOLOGY (2019)
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
Frederick F. Lang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients A phase I/II trial
Alfredo Marinelli et al.
MEDICINE (2018)
Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study
Giammaria Fiorentini et al.
INTEGRATIVE CANCER THERAPIES (2018)
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
Brian M. Alexander et al.
CLINICAL CANCER RESEARCH (2018)
IMST-26. TUMOR TREATING FIELDS EXPOSURE OF TUMOR CELLS INDUCE ACTIVATION PHENOTYPE IN IMMUNE CELLS
Talia Holtzman
NEURO-ONCOLOGY (2017)
Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume
Andrea Di Cristofori et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields
Edwin Chang et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller et al.
LANCET ONCOLOGY (2017)
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma Clinical Trial/Experimental Study
Lei Wang et al.
MEDICINE (2017)
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
Karsten Geletneky et al.
MOLECULAR THERAPY (2017)
Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group
Tomokazu Aoki et al.
NEUROLOGIA MEDICO-CHIRURGICA (2017)
Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma
Johann Klein et al.
ONCOLOGY (2017)
Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life
Linda Stoeckelmaier et al.
WORLD NEUROSURGERY (2017)
Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis
Sergey V. Roussakow
BMJ OPEN (2017)
GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status
P. Perez-Segura et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Gaspar Reynes et al.
ANTI-CANCER DRUGS (2016)
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
Eric T. Wong et al.
BMC CANCER (2016)
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study
Giuseppe Lombardi et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Timothy F. Cloughesy et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
George Ansstas et al.
CASE REPORTS IN NEUROLOGY (2016)
Treatment of recurrent malignant gliomas with 13-cis-retinoic acid naphthalene triazole
Pi-Feng Jia et al.
NEUROLOGICAL SCIENCES (2015)
Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells
Moshe Giladi et al.
SCIENTIFIC REPORTS (2015)
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation
Eric T. Wong et al.
CANCER MEDICINE (2015)
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study
Bruno F. Carvalho et al.
ONCOLOGY RESEARCH AND TREATMENT (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schoenfeld et al.
MOLECULAR THERAPY (2015)
Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma
Michaela Tonder et al.
CHEMOTHERAPY (2014)
ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
Johannes Rieger et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
The role of cytotoxic chemotherapy in the management of progressive glioblastoma
Jeffrey J. Olson et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
Seunggu J. Han et al.
NEURO-ONCOLOGY (2014)
Carmustine (BCNU) plus Teniposide (VM26) in Recurrent Malignant Glioma
Frederic Mack et al.
ONCOLOGY (2014)
Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults
Kimberly P. Kicielinski et al.
MOLECULAR THERAPY (2014)
A phase II trial of oral gimatecan for recurrent glioblastoma
Jethro Hu et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
Matteo Santoni et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Antonio Omuro et al.
NEURO-ONCOLOGY (2013)
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Andrew D. Norden et al.
NEURO-ONCOLOGY (2013)
Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme
Eleftherios Archavlis et al.
BMJ OPEN (2013)
Oncolytic Virus Therapy for Glioblastoma Multiforme Concepts and Candidates
Guido Wollmann et al.
CANCER JOURNAL (2012)
Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Balveen Kaur et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2012)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp et al.
EUROPEAN JOURNAL OF CANCER (2012)
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma
Enrico Franceschi et al.
NEURO-ONCOLOGY (2012)
Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields
Aaron Michael Rulseh et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre- and Post-tumor Resection for Recurrent GBM
James M. Markert et al.
MOLECULAR THERAPY (2009)
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
Peter Forsyth et al.
MOLECULAR THERAPY (2008)
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Eilon D. Kirson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
AI Freeman et al.
MOLECULAR THERAPY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
EA Chiocca et al.
MOLECULAR THERAPY (2004)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
